| HOME >> MEDICINE >> TECHNOLOGY |
NicOx' NCX 1510. A potential partnership and further development of the
NLA program may include NCX 1510 or could exclude NCX 1510 and instead
focus on other formulations of Orexo's NLA technology
-- In October 2007, NicOx and Ferrer Grupo International jointly presented
clinical and preclinical results from their collaboration at the 21st
World Congress of Dermatology
-- In July 2007, NicOx appointed Pascal Pfister MD as Chief Scientific
Officer (CSO). Dr. Pfister reports to Michele Garufi, Chairman and CEO,
and has overall responsibility for NicOx' Research and Development
(R&D) activities. Dr. Pfister brings extensive experience and
leadership to NicOx from his 19 year career at Novartis and Sandoz
-- In October 2007, NicOx opened its U.S. headquarters in Warren, New
Jersey, where the Company has based its newly established Commercial
Affairs and North American Clinical Operations departments. This
followed the appointment of Sanjiv Sharma as Vice President of
Commercial Affairs in April 2007, who is also head of the U.S. Office.
Sanjiv brings extensive marketing and sales management experience to
NicOx, from his previous positions at Biovail Pharmaceutical Inc. and
Sanofi-Aventis and its predecessor companies
Review of the financial results on December 31, 2007 and 2006:
Revenues
In 2007, NicOx' revenues increased by euro 11.0 million to reach euro
20.6 million, compared to euro 9.6 million in 2006. This significant
increase results from the following payments that were entirely recognized
as revenues in 2007:
-- Euro 5.0 million received from Merck in January 2007, following the
initiation of toxicology studies on the first development candidate
which had been recently selected, in the
'/>"/>
| SOURCE NicOx S.A. Copyright©2008 PR Newswire. All rights reserved |